Proscia Strengthens Leadership Position In Global Diagnostic Pathology Market
2024年6月26日 - 9:00PM
Proscia®, a global leader in AI-enabled pathology solutions for
precision medicine, has expanded its leadership position in the
diagnostic pathology market. The company has grown its clinical
customer base by more than 100% in the past year. Among its other
highlights, Proscia was recognized by KLAS Research in a June 2024
Emerging Company Spotlight report and released findings from a
study conducted with Quest Diagnostics, a leading provider of
diagnostic information services, on the impact of its AI-enabled
workflows.
Proscia’s momentum comes as digital pathology experiences a new
surge in global demand. Laboratories are increasingly seeking to
expand their businesses by capitalizing on the real-world data
generated in the shift from microscope to images; each whole slide
image contains over 1 billion pixels that can advance the next
blockbuster therapies. With its Concentriq® software platform,
Proscia enables laboratories to fully leverage their data while
optimizing operations and laying the foundation to unlock new
insights with AI applications.
KLAS Emerging Company Spotlight confirms Concentriq
delivers immediate value and customers trust ProsciaEarly
data from KLAS shows the majority of Proscia’s customers surveyed
saw immediate benefits from Concentriq, and all such customers
achieved outcomes within 6 months of deploying the enterprise
pathology platform. Impacts cited include improving turnaround
times, attracting more talent, and creating a real-world data
archive for fueling research and development.
The KLAS report additionally reveals that these customers are
impressed with both the level of support they receive and Proscia’s
pathology expertise. They also awarded Proscia an ‘A+’ rating for
its executive team’s involvement. Working with a trusted partner
that offers a world-class software platform has led 100% of
Proscia’s customers surveyed to say they would buy again.
Read KLAS Research’s Emerging Company Spotlight on Concentriq by
accessing the full report here.
Quest Diagnostics study highlights Concentriq’s scalable
approach to AIUsing Concentriq's AI-enabled workflows with
Ibex’s clinical-grade, AI-powered Prostate* solution, pathologists
at Quest Diagnostics were able to sign out 2.9 cases per hour
instead of 1.2. The offering was designed to assist pathologists in
improving the detection and grading of prostate cancer by
streamlining pathologists’ review of tissue samples that have been
scanned at high resolution to create digital slides, or whole slide
images (WSIs), which pathologists can then view.
The study included 180 randomized prostate cases from adult (21
or older) subjects. 100% of the pathologists who participated in
the study stated they would be much more likely to adopt AI at the
study’s conclusion. Quest Diagnostics, through its AmeriPath and
Dermpath Diagnostics subspecialty pathology businesses, employs
over 400 pathologists at its nationwide network of clinical
laboratories.
“We are thrilled to help demonstrate the impact of AI-driven
pathology through this study with Proscia and Ibex Medical
Analytics,” said Kristie Dolan, Senior Vice President and General
Manager of Oncology & Pathology at Quest Diagnostics. “The
findings provide further evidence that pathology is undergoing an
unprecedented transformation, and we will continue to collaborate
with world-class companies to remain at the forefront of this
innovation.”
View and download the study in its entirety here.
Recent FDA clearance enables Proscia to bring its
software to U.S. diagnostic pathology marketIn February,
Proscia received FDA 510(k) clearance for its Concentriq AP-Dx**
solution for the purpose of primary diagnosis. This milestone not
only opened the U.S. diagnostic pathology market to Proscia but
also enables its distribution partners Agilent Technologies and
Siemens Healthineers to provide its software to their U.S.-based
customers.
Proscia’s 510(k) clearance further builds on its regulatory
credentials. It was the first company to receive CE-IVDR
certification to advance digital pathology primary diagnosis in the
European Union and has products licensed in Canada and cleared in
the United Kingdom among other countries.
“More and more laboratories are putting their trust in Proscia
to help them deliver faster results, provide confident diagnoses,
and expand their businesses, especially now that we have FDA
clearance,” said David West, CEO. “It’s incredibly rewarding to see
the impact our Concentriq platform and team are delivering. This is
evident from the positive feedback our customers shared with KLAS
as well as Quest Diagnostics’ impressive study results.”
*The Ibex suite includes solutions which are for Research Use
Only (RUO) in the United States and not cleared by the FDA.
Multiple solutions are CE marked (IVDD and IVDR) and registered
with the UK MHRA. For more information, including indication for
use and regulatory approval in other countries, contact Ibex
Medical Analytics.
**Concentriq AP-Dx is cleared (K230839) for clinical use with
the Hamamatsu NanoZoomer S360MD Slide scanner in the United
States.
About ProsciaProscia is a software company
accelerating the transformation to digital pathology to change the
way we understand diseases like cancer. Its Concentriq enterprise
pathology platform and powerful AI applications are advancing the
150-year-old standard of research and diagnosis towards a
data-driven discipline, unlocking new insights that accelerate
R&D, improve patient outcomes, and fulfill the promise of
precision medicine. Leading diagnostic laboratories and 14 of the
top 20 pharmaceutical companies rely on Proscia’s software each
day. For more information, visit proscia.com.
Contact
Sydney FenkellHead Of Marketing
Communications215-816-3436sydney@proscia.com